Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 34

Related Articles by Review for PubMed (Select 18223322)

1.

hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature.

Lapointe J, Malhotra S, Higgins JP, Bair E, Thompson M, Salari K, Giacomini CP, Ferrari M, Montgomery K, Tibshirani R, van de Rijn M, Brooks JD, Pollack JR.

Am J Surg Pathol. 2008 Feb;32(2):205-9. doi: 10.1097/PAS.0b013e318124a865.

PMID:
18223322
2.

Biomarker discovery in urogenital cancer.

Said J.

Biomarkers. 2005 Nov;10 Suppl 1:S83-6. Review.

PMID:
16298916
3.

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL.

Ann Intern Med. 2008 Mar 18;148(6):435-48. Epub 2008 Feb 4. Review. Erratum in: Ann Intern Med. 2008 Jun 3;148(11):888.

PMID:
18252677
4.

Integrating biomedical knowledge to model pathways of prostate cancer progression.

Morris DS, Tomlins SA, Rhodes DR, Mehra R, Shah RB, Chinnaiyan AM.

Cell Cycle. 2007 May 15;6(10):1177-87. Epub 2007 May 5. Review.

5.

The role of tissue microarrays in prostate cancer biomarker discovery.

Datta MW, True LD, Nelson PS, Amin MB.

Adv Anat Pathol. 2007 Nov;14(6):408-18. Review.

PMID:
18049130
6.

Epigenetic mechanisms in the biology of prostate cancer.

Schulz WA, Hoffmann MJ.

Semin Cancer Biol. 2009 Jun;19(3):172-80. doi: 10.1016/j.semcancer.2009.02.006. Epub 2009 Feb 20. Review.

PMID:
19429481
7.

[Biomarkers for prostate cancer in predicting diagnosis, staging and prognosis].

Ohori M.

Gan To Kagaku Ryoho. 2009 Jan;36(1):6-10. Review. Japanese.

PMID:
19151558
8.

The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.

Kehinde EO, Maghrebi MA, Anim JT.

Can J Urol. 2008 Apr;15(2):3967-74. Review.

PMID:
18405443
9.

Gene expression alterations in human prostate cancer.

Luo JH.

Drugs Today (Barc). 2002 Oct;38(10):713-9. Review.

PMID:
12582456
10.

[Microarrays].

Grimm MO, Hartmann FH, Schulz WA.

Urologe A. 2004 Jun;43(6):653-8. Review. German.

PMID:
15138693
11.

Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer.

Kumar-Sinha C, Chinnaiyan AM.

Urology. 2003 Dec 29;62 Suppl 1:19-35. Review.

PMID:
14747039
12.

Molecular genetics of prostate cancer: clinical translational opportunities.

Vecchione A, Gottardo F, Gomella LG, Wildemore B, Fassan Ms, Bragantini E, Pagano F, Baffa R.

J Exp Clin Cancer Res. 2007 Mar;26(1):25-37. Review.

PMID:
17550130
13.

The role of molecular genetics in chemoprevention studies of prostate cancer.

Ross RK.

IARC Sci Publ. 2001;154:207-13. Review.

PMID:
11220660
14.

Molecular staging of prostate cancer in the year 2007.

Schlomm T, Erbersdobler A, Mirlacher M, Sauter G.

World J Urol. 2007 Mar;25(1):19-30. Epub 2007 Mar 2. Review.

PMID:
17334767
15.

Predicting prostate cancer behavior using transcript profiles.

Nelson PS.

J Urol. 2004 Nov;172(5 Pt 2):S28-32; discussion S33. Review.

PMID:
15535439
16.

Molecular changes in prostatic cancer.

Bott SR, Arya M, Shergill IS, Williamson M.

Surg Oncol. 2005 Aug;14(2):91-104. Review.

PMID:
15993579
17.

Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel.

Amaro A, Esposito AI, Gallina A, Nees M, Angelini G, Albini A, Pfeffer U.

Cancer Metastasis Rev. 2014 Sep;33(2-3):657-71. doi: 10.1007/s10555-013-9470-4. Review.

18.
19.

Molecular biology and the staging of prostate cancer.

Marandola P, Bonghi A, Jallous H, Bombardelli E, Morazzoni P, Gerardini M, Tiscione D, Albergati F.

Ann N Y Acad Sci. 2004 Dec;1028:294-312. Review.

PMID:
15650255
20.

Stem cell origin of death-from-cancer phenotypes of human prostate and breast cancers.

Glinsky GV.

Stem Cell Rev. 2007 Jan;3(1):79-93. Review.

PMID:
17873385
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk